Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Polypharmacy is common in bipolar I disorder, but not always necessary. A growing focus on "deprescribing" urges clinicians to regularly reassess whether every medication on a patient's list is still earning its place — especially since complex regimens can make patients 2.5x more likely to stop taking their meds altogether.
Clinicians managing bipolar I disorder (BD-I) are well-trained in starting medications — but far less so in stopping them. A growing movement around "deprescribing" is pushing psychiatry to rethink long-standing treatment regimens, particularly as patients accumulate medications over years of care, sometimes to manage the side effects of other drugs.
The stakes are real: a secondary analysis of 482 adults with bipolar disorder found that those on three or more medications had roughly 2.5 times the odds of non-adherence compared to those on simpler regimens. At the same time, a meta-analysis of 22 RCTs found that continuing medication in stable BD-I patients was associated with a 39% lower relative risk of mood episode recurrence versus stopping — a reminder that deprescribing isn't about cutting corners, it's about cutting what's unnecessary.
Key Takeaways:
Why it matters: Simplifying treatment regimens isn't just about convenience — it can meaningfully improve adherence, quality of life, and long-term outcomes for patients living with a complex, lifelong condition.